Novo Nordisk A/S Class B

As of June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh carries a market capitalization of 7.17T, placing it among publicly traded companies globally. Its enterprise value stands at 7.65T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh has 4.43T shares outstanding.

As of June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh trades at a trailing price-to-earnings ratio of 9.12. The price-to-sales ratio is 3.22, and the price-to-book ratio stands at 6.38.

As of June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh trades at an EV/EBITDA multiple of 9.30 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh trades at an EV/FCF ratio of 31.23, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 7.65T versus a market cap of 7.17T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.33, indicating elevated leverage, while an interest coverage ratio of 273.09 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh posted a return on equity (ROE) of 59.82, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 33.40 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.62, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 37.19, useful for judging operating efficiency across full business cycles. The company generates approximately 23.68M in revenue per employee across its workforce of 70,671.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.31 indicates how many times Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh recorded 164.09B in income tax expense. That works out to an effective tax rate of 21.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 755.55B, leaving 591.45B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 21, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh's stock has declined approximately 24.86% over the past 52 weeks. The 50-day moving average sits at 1.42, while the 200-day moving average is 1.48.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh generated 1.67T in revenue and converted that into 591.45B in net income, yielding earnings per share of 0.18. EBITDA reached 822.55B, while operating income came in at 721.76B.

As of June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh holds 228.48B in cash and equivalents against 711.75B in total debt, resulting in a net debt position of 485.81B. Total book value stands at 1.12T, with working capital of -154.35B providing operational flexibility.

Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh produced 669.87B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -427.13B in capital expenditures, free cash flow totaled 242.74B - equivalent to 0.07 per share.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh posted a gross margin of 80.65, reflecting its pricing power and cost economics. The operating margin of 43.13 and net profit margin of 35.35 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh paid dividends of 0.08 per share. The dividend payout ratio of 44.64 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.49, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.58, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh shareholders.

As of June 30, 2026, Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh has an Altman Z-Score of 4.54, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.